European Multidisciplinary Cancer Congress (EMCC) no comments
Posted at 12:03 pm in CLTA News
New drug formulations, biological agents, combination therapies and the latest pharmaceutical developments designed to improve outcomes in patients with a wide range of cancers were highlighted at EMCC 2001. Here are just a few of the highlights: Progression-free survival (PFS) in patients with HER2-positive metastatic breast cancer (MBC) cancer was improved by more than 40% in a clinical trial …